Best in Biotech 28 Nov 2024
Six antisense oligonucleotide companies shaping the future of genetic medicine
Learn more about six antisense oligonucleotide companies shaping the future of genetic medicine, just as the market is expected to grow.
Don't miss out on the next big biotech breakthrough
Get all the latest updates straight into your inbox!
Newsletter Signup - Home CTA
"*" indicates required fields
-
In DepthDecember 2, 2024The rise of cancer vaccines: A new era in immunotherapy
-
News and TrendsNovember 29, 2024Trump’s healthcare picks: Who they are and what they mean for the biopharma industry
-
PodcastNovember 29, 2024Can biotech beat mosquito-borne diseases?
- Latest Posts
- Popular Posts
In Depth 27 Nov 2024Charcot–Marie–Tooth disease: what’s going on in the clinical field?
In this article, we take a look at the various treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease.
Best in Biotech 26 Nov 2024Seven miRNA-focused companies pioneering new therapies in 2024
Delve into the field of miRNA with seven companies with miRNA-focused candidates in the pipeline in 2024, from oncology to neurodegeneration.
Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success
Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of cancer treatment.
News and Trends 25 Nov 2024Evotec on the brink of acquisition: At what cost for the biotech industry?
As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech landscape.
In Depth 22 Nov 2024Can AlphaFold3’s open-source platform revolutionize the way we discover drugs?
Find out how Google DeepMind’s AlphaFold3 platform could help scientists revolutionize the field of drug discovery.ADVERTISEMENT
ADVERTISEMENT
Podcast 22 Nov 2024Could antigen modulation address autoimmune diseases?
To tell us more about antigen modulation this week is Pete Joyce, CEO and co-founder of Grey Wolf Therapeutics.
In Depth 21 Nov 2024Huntington’s disease: a therapeutic field on a bumpy ride
For years, biotechs have been trying to develop medicines to cure the disease but much to no avail. Now, as clinical studies advance, there is hope.
Best in Biotech 21 Nov 2024Eight areas where gene therapy shines
Delve into the numerous applications of gene therapy, from cancer to hematological disorders and respiratory diseases.
In Depth 20 Nov 2024Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024
The hypoparathyroidism treatment space has made quite a buzz this year with a major drug approval, acquisition, and significant advances in clinical trials.
Best in Biotech 19 Nov 2024Six bispecific antibody companies you should know about
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
In Depth 18 Nov 2024What is Abcam’s founder, Jonathan Milner, up to?
Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy.
Expert Advice 2 Feb 20245 biotech career paths where demand is skyrocketing
Check out five important biotechnology careers that are currently in high demand, and likely still will be in the coming years.
Best in Biotech 12 Mar 2024The twelve hottest biotech companies in the Boston area
Explore Boston’s vibrant biotech landscape with twelve innovative companies leading the charge in life sciences research.
In Depth 12 Feb 2024RNA editing set to take off: could DNA’s short-lived cousin overcome the limitations of CRISPR gene editing?
Find out all about about RNA editing, as two candidates have just managed to reach the clinic for the first time.
In Depth 15 Jan 2024The future of diabetes treatment: Is a cure possible?
Diabetes has become an epidemic. Science is striving to find a diabetes treatment that can cure this chronic disease, but how close are we?
In Depth 8 Feb 2024Could we see a new dawn for hair loss treatments?
Discover the latest advances in hair loss treatments, from topical therapies to the the groundbreaking potential of JAK inhibitors.
Best in Biotech 5 Jan 2024Five AI drug discovery companies you should know about
Take a look at five of the top AI drug discovery companies around today, using their technology to speed up the drug discovery process.
Expert Advice 15 Mar 2024Is biotechnology a good career? Here are the pros and cons
Find out about the pros and cons of pursuing a career in biotechnology, from competitive salaries to dealing with regulatory hurdles.
In Depth 9 Feb 2024Biotech job market 2024: what to expect?
The past year saw pipeline cuts and downsizing plans strike the biotech industry. Does the biotech job market seem to be looking up this year?
Podcast 19 Jan 2024Epigenetic editing – the power of CRISPR without cutting DNA
Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells. This enables in vivo or ex vivo delivery via a single viral vector. Epic’s lead program, EPI-321, is in IND-enabling studies […]
Best in Biotech 12 Apr 20246 biotechnology universities in the US nurturing tomorrow’s trailblazers
Discover the top biotechnology universities in the US offering cutting-edge programs that are helping students find a career in biotech.
In Depth 8 Jul 2024Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR
Find out how the recent discovery of a molecular oddity found in bacteria has led to a new gene editing technique.
Best in Biotech 13 Feb 2024Eight biotechs thriving in Seattle
In this article, let us take a look at some of the major biotech companies in Seattle that are contributing to the biotech industry at large.
ADVERTISEMENT